Navigation Links
DOR BioPharma to Present at the Rodman & Renshaw Annual Global Investor Healthcare Conference
Date:9/3/2009

nes against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its cash expenditures will not exceed projected levels, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec(R) for gastrointestinal GVHD include the risks that: the FDA's requirement that DOR conduct additional clinical trials to demonstrate the safety and efficacy of orBec(R) will take a significant amount of time and money to complete and positive results leading to regulatory approval cannot be assumed; DOR is dependent on the expertise, effort, priorities and contractual obligations of third parties in the clinical trials, manufacturing, marketing, sales and distribution of its products; orBec(R) may not gain market acceptance if it is eventually approved by the FDA; and others may develop technologies or products superior to orBec(R). Factors affecting the development and use of DOR201 and LPM(TM) are similar to those affecting orBec(R). These and other factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, DOR's most recent reports on Forms 1
'/>"/>
SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Eiger BioPharmaceuticals Appoints Paul Truex to Board of Directors
2. DOR BioPharma Reports 2nd Quarter and 1st Half 2009 Financial Results and Reviews Recent Accomplishments
3. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
5. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
6. DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
7. PDL BioPharma to Present at BMO Capital Markets Healthcare Conference on August 5, 2009
8. Alexandria Real Estate Equities, Inc. Signs Biopharmaceutical Company, Lilly, as Anchor New York City Tenant at the Alexandria Center for Science and Technology
9. Big Pharma to Big Biopharma: Frost & Sullivan Examines the Latest M&A Trends and Opportunities
10. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
11. DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... in Iraq and Afghanistan, more than 300,000 soldiers have ... caused by exposure to bomb blasts and in ... of traumatic brain injury can range from the mild, ... impairments in memory and cognition. , Since 2007, ... importance and complexity of this problem, and has made ...
(Date:9/29/2014)... food security, emerging diseases and biodiversity loss requires ... in Science Express that was co-authored ... College of Agriculture and Life Sciences. , For ... scientists has reviewed progress in addressing a broad ... management using approaches that consider evolutionary histories and ...
(Date:9/29/2014)... (PRWEB) September 29, 2014 Transparency Market ... Synthesis - SPPS, LPPS, HPPS, by Application - Cancer, ... & Generic and by Delivery) - Global Industry Analysis, ... states that the global peptide therapeutics market was worth ... US$25.4 billion by 2018 at an 8.7% CAGR. , ...
(Date:9/29/2014)... , Sept. 29, 2014 /PRNewswire/ - SQI Diagnostics Inc. ... develops and commercializes proprietary technologies and products for advanced ... Peter Winkley to Chairman of the Board ... Mr. Ricks will continue to serve as a Director ... to the Company.  "We are very ...
Breaking Biology Technology:Modeling shockwaves through the brain 2Modeling shockwaves through the brain 3Modeling shockwaves through the brain 4Evolutionary biology: It's not just for textbooks anymore 2Evolutionary biology: It's not just for textbooks anymore 3Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 2Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 3SQI Diagnostics Announces New Chairman of Board of Directors 2
... by hiring laboratory reagent and diagnostics industry veteran , ... ... Inc., a high-tech provider of rapid prototyping and manufacturing services ... President of Operations. Dr. Anderson brings years of entrepreneurial and ...
... for November 6, 2008 at 10:00 a.m. EST, EAST ... ) today reported financial results for,the three and nine months ... of 2008 was $18.2 million or $0.34 per basic and ... net loss of $14.6,million or $0.28 per basic and diluted ...
... announced today the,submission of the response to the ... in Single Dose Containers). In an,Approvable Letter received ... with respect to chemistry, manufacturing, and controls (CMC)., ... complete response as a Class 2,resubmission, under which ...
Cached Biology Technology:ALine, Inc. Expands Management, Adding Roger Anderson, Ph.D., as VP of Operations 2Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results 2Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results 3Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results 4Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results 5Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results 6Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results 7Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results 8Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results 9Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results 10SALVAT Announces Submission of Complete Response to FDA Approvable Letter for CETRAXAL(R) 2
(Date:9/29/2014)... 2014 Growing Demand From ... Increasing Security Concerns Continue to Propel Biometrics Market ... is one of the fastest growing biometrics ... systems, majorly in various government projects such as ... based biometrics dominates the country,s biometrics market, with ...
(Date:9/29/2014)... release is available in French . ... - The number of days an expectant mother was ... the epigenetic profile of her child, a new study ... and McGill University have detected a distinctive ,signature, in ... the massive Quebec ice storm. Five months after the ...
(Date:9/28/2014)... at the University of California, Santa Cruz, suggest that ... genomes of primates drove the evolution of complex regulatory ... cell of our bodies. , The arms race ... "jumping genes") and the genes that have evolved to ... the first time, identified genes in humans that make ...
Breaking Biology News(10 mins):India Biometrics Market to Surpass USD2.7 Billion by 2019, Finds TechSci Research Study 2India Biometrics Market to Surpass USD2.7 Billion by 2019, Finds TechSci Research Study 3Human genome was shaped by an evolutionary arms race with itself 2Human genome was shaped by an evolutionary arms race with itself 3Human genome was shaped by an evolutionary arms race with itself 4
... to combat osteoporosis and other human common diseases is ... project "BlueGenics" which has received funding of EUR 6 ... team, coordinated by Professor Dr. Werner E.G. Mller from ... Medical Center, intends to identify and to utilize genetic ...
... believe that this knowledge may be important for the ... health issues, that modern science still hasn,t been able ... Center for Infectious Medicine at Karolinska Institutet and the ... time, it,s important to emphasize that humans have lived ...
... 2012 More than 100 academic institutions and ... initiative: Mathematics of Planet Earth (MPE) 2013. This ... mathematics in tackling global problems, including natural disasters ... sustainability; and pandemics. MPE2013 partners will sponsor workshops, ...
Cached Biology News:Launch of the EU large-scale integrating project 'BlueGenics' to combat osteoporosis 2Launch of the EU large-scale integrating project 'BlueGenics' to combat osteoporosis 3How the common 'cat parasite' gets into the brain 2Mathematicians tackle global issues 2Mathematicians tackle global issues 3
... stain kits are optimized for use ... Dodeca stainers. This silver stain kit ... in polyacrylamide gels and are mass ... concentrate, silver reagent concentrate, background reducer ...
... This PTC-100 thermal cycler holds 96 x ... Hot Bonnet heated lid incorporates a thumbwheel ... seal PCR vessels for oil-free cycling. Peltier ... NIST-traceable calibration and ramping rates of up ...
BioGenex IHC Kits for Rodent Tissues are designed for immunohistochemistry on rodent and rabbit tissues that are closely related to the source of the primary antibody. This kit comes with rat seconda...
EZ-DeWax is a one-step solution that simultanously removes paraffin from and rehydrates formalin-fixed, paraffin embedded tissue...
Biology Products: